The Inflation Reduction Act (IRA) made changes to the way drugs are covered and reimbursed in Medicare. It has been ...

With a breakout from a downward-sloping channel, the Nifty is expected to march toward the 25,600–25,700 zone, while support ...

Nearly 150 stocks on the BSE touched their 52-week highs, including Glenmark Pharma, LT Finance, Apollo Hospitals, Navin ...

The Howard County Board of Education is suing Eli Lilly and Co., Novo Nordisk, CVS, UnitedHealth Group and several other drug ...

Investors appear concerned that the payment reductions could negatively impact diabetes device makers, as many patients using continuous glucose monitors (CGMs) and insulin pumps rely on Medicare ...

Canadian Insulin simplifies the process for U.S. customers by offering a secure, user-friendly platform for purchasing medications, including insulin and GLP-1 agonists like Ozempic.

Hundreds of lawsuits allege that insulin manufacturers and pharmacy benefit managers colluded to raise prices. The manufacturers deny the claims.

While insulin price reductions are a notable victory, out-of-pocket costs for prescription medications continue to trend upward. Since 2014, prescription list prices have grown nearly 40%.

Biosimilar insulin glargine access in Europe correlates with significant price reductions of originator products, enhancing affordability and accessibility. The study observed a 21.6% average ...

Minnesota Attorney General Keith Ellison and pharmaceutical company Novo Nordisk reached a settlement to cap insulin costs at $35 per month. Insulin prices rose by around 184% in a decade from 2012 to ...

If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in their favor.